Pancreatic cancer is the fourth most common cause of cancer-related deaths in the United States and the twelfth worldwide. It is estimated that more than 45,000 new cases of pancreatic cancer were diagnosed in 2013, resulting in more than 38,000 deaths. Pancreatic cancer has an extremely poor prognosis, highlighting the importance of increased research and the development of novel therapeutics for its treatment.
|Indication||Cell Line||Available Models|
|Pancreatic Carcinoma||AsPC-1, PANC-1, MIA PaCa-2||Xenograft, Orthotopic,
Cancer Stem Cells, In Vitro Assays
|Xenograft||Tumor cells are implanted subcutaneously in immunocompromised rats or mice||Variable||Tumor volume, histology, cytokine induction, protein, and RNA expression.|
|Orthotopic||Cells are implanted directly into the desired organ site in immunocompromised rats or mice|
|Cancer Stem Cells||Tumor initiating cells are enriched from a heterogeneous bulk tumor cell population. Cancer stem cells are studies in comparison to the “parent” line and can be assessed in 3-D culture in vitro or implanted into animals in vivo.||In vitro: Tumorsphere Formation, Proliferation, Survival, Migration, FACS profile.
In Vivo: Tumor volume, metastasis, histology, cytokine induction, protein and RNA Expression
|In Vitro Assays||Assays for: Proliferation and survival, migration and invasion, tumorspheres/colony formation||Tumor cell growth, invasiveness and survival|
|* Several models are compatible with IVIS imaging for in-life monitoring of disease progression.|
Orthotopic Model of Pancreatic Cancer
Primary tumor growth in the mouse pancreas as a result of direct injection of BxPC3 cancer cells.
(A)Representative IVIS Images Showing the Treatment Effects of Dosing with Gemcitabine on Orthotopic Pancreatic Cancer Tumor Growth (B) Radiance values for each animal are quantitated and the average radiance presented to demonstrate the efficacy of therapeutics in treating pancreatic tumors.
Cancer Stem Cell Model of Pancreatic Cancer
Cancer stem cells were enriched from “parent line” BxPC3 cells using positive selection for the CD44+ population. The left panel shows the FACS profile of stem cell markers CD44+, CD133+ and CD24+ on this enriched population. The middle panel shows the differences in proliferation rates between the parent line and the enriched cancer stem cells. The panel on the right represents differences in invasive migration between the parent line and the enriched cancer stem cells.